BioLineRx (NASDAQ:BLRX) Downgraded by StockNews.com to “Sell”

BioLineRx (NASDAQ:BLRX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright reduced their price objective on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research report on Monday, November 25th.

BioLineRx Stock Down 1.2 %

Shares of NASDAQ:BLRX traded down $0.04 during midday trading on Tuesday, hitting $3.18. 13,420 shares of the company’s stock were exchanged, compared to its average volume of 65,048. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The stock has a 50 day moving average price of $3.83 and a 200-day moving average price of $12.15. The company has a market cap of $10.59 million, a PE ratio of -0.36 and a beta of 1.39. BioLineRx has a 12 month low of $2.88 and a 12 month high of $56.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.